Muthoni Junghae

Muthoni Junghae

Auto-generated profile, based on publicly available information

Muthoni Junghae

Division of Global HIV and TB, US Centers for Disease Control and Prevention, Kenya

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 January 2017 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
MKMiwako Kobayashi
Miwako Kobayashi
LCLaura M. Conklin
Laura M. Conklin
GBGodfrey Bigogo
Godfrey Bigogo
GJGeofrey Jagero
Geofrey Jagero
LHLee Hampton
Lee Hampton
RBRobert F. Breiman
Robert F. Breiman
Pneumococci are spread by persons with nasopharyngeal colonization, a necessary precursor to invasive disease. Pneumococcal conjugate vaccines can prevent colonization with vaccine serotype strains. In 2011, Kenya became one of the first African countries to introduce the 10-valent pneumococcal conjugate vaccine (PCV10) into its national immunization program. Serial cross-sectional colonization surveys were conducted to assess baseline pneumococcal colonization, antibiotic resistance patterns, and factors associated with resistance. Annual surveys were conducted in one urban and one rural site during 2009 and 2010 among children aged <5 years. To reflect differences in vaccine target population, recruitment was age-stratified in Kibera, whereas a simple random sample of children was drawn in Lwak. Nasopharyngeal swabs were collected from eligible children. Pneumococci were isolated and serotyped. Antibiotic susceptibility testing was performed using the 2009 isolates. Antibiotic nonsusceptibility was defined as intermediate susceptibility or resistance to ≥1 antibiotics (i.e., penicillin, chloramphenicol, levofloxacin, erythromycin, tetracycline, cotrimoxazole, and clindamycin); multidrug resistance (MDR) was defined as nonsusceptibility to ≥3 antibiotics. Weighted analysis was conducted when appropriate. Modified Poisson regression was used to calculate factors associated with antibiotic nonsusceptibility. Of 1,087 enrolled (Kibera: 740, Lwak: 347), 90.0% of these were colonized with pneumococci, and 37.3% were colonized with PCV10 serotypes. There were no differences by survey site or year. Of 657 (of 730; 90%) isolates tested for antibiotic susceptibility, nonsusceptibility to cotrimoxazole and penicillin was found in 98.6 and 81.9% of isolates, respectively. MDR was found in 15.9% of isolates and most often involved nonsusceptibility to cotrimoxazole and penicillin; 40.4% of MDR isolates were PCV10 serotypes. In the multivariable model, PCV10 serotypes were independently associated with penicillin nonsusceptibility (Prevalence Ratio: 1.2, 95% CI 1.1–1.3), but not with MDR. Before PCV10 introduction, nearly all Kenyan children aged <5 years were colonized with pneumococci, and PCV10 serotype colonization was common. PCV10 serotypes were associated with penicillin nonsusceptibility. Given that colonization with PCV10 serotypes is associated with greater risk for invasive disease than colonization with other serotypes, successful PCV10 introduction in Kenya is likely to have a substantial impact in reducing vaccine-type pneumococcal disease and drug-resistant pneumococcal infection.

1 December 2015 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
LCLaura M. Conklin
Laura M. Conklin
GBGodfrey Bigogo
Godfrey Bigogo
GJGeofrey Jagero
Geofrey Jagero
LHLee Hampton
Lee Hampton
MJMuthoni Junghae
Muthoni Junghae
DFDaniel R. Feikin
Daniel R. Feikin
Streptococcus pneumoniae is a leading cause of pneumonia, meningitis and sepsis in developing countries, particularly among children and HIV-infected persons. Pneumococcal oropharyngeal (OP) or nasopharyngeal (NP) colonization is a precursor to development of invasive disease. New conjugate vaccines hold promise for reducing colonization and disease. Prior to introduction of 10-valent pneumococcal conjugate vaccine (PCV10), we conducted a cross-sectional survey among HIV-infected parents of children 250 were protective (OR = 0.6; 95 % CI 0.4, 0.9 and OR = 0.5; 95 % CI 0.2, 0.9, respectively); other associations were not identified. Among 309 isolates tested from all parents, 255 (80.4 %) were penicillin non-susceptible (MIC ≥0.12 μg/ml). Prevalence of pneumococcal colonization is high among HIV-infected parents in rural Kenya. If young children are the pneumococcal reservoir for this population, PCV10 introduction may reduce vaccine-type colonization and disease among HIV-infected parents through indirect protection.

2 November 2021 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Open access
VOValarie Opollo
Valarie Opollo
ENEmmanuel Nyakeriga
Emmanuel Nyakeriga
LKLeonard Kingwara
Leonard Kingwara
ASAlex Sila
Alex Sila
MOMacxine Achieng Oguta
Macxine Achieng Oguta
MJMuthoni Junghae
Muthoni Junghae
Background: Estimating cause-related mortality among the dead is not common, yet for clinical and public health purposes, a lot can be learnt from the dead. HIV/AIDS accounted for the third most frequent cause of deaths in Kenya; 39.7 deaths per 100,000 population in 2019. OraQuick® has previously been validated on oral fluid and implemented as a screening assay for HIV self-testing in Kenya among living subjects. We assessed the feasibility and diagnostic accuracy of OraQuick® for HIV screening among decedents. Methods: Trained morticians collected oral fluid from 132 pre- and post-embalmed decedents aged >18 months at Jaramogi Oginga Odinga Teaching and Referral Hospital mortuary in western Kenya and tested for HIV using OraQuick®. Test results were compared with those obtained using the national HIV Testing Services algorithm on matched pre-embalming whole blood specimens as a gold standard (Determine® HIV and First Response® HIV 1-2-O). We calculated positive predictive values (PPV), negative predictive values (NPV), Area Under Curve (AUC), sensitivity and specificity of OraQuick® compared to the national HTS algorithm. Results: OraQuick® had similar sensitivity of 92.6%, (95.0% confidence interval (CI):75.7- 99.1) on pre- and post-embalmed samples compared to the gold standard. Specificity was 97.1% (95.0% CI:91.9-99.4) and 95.2%, (95.0% CI:89.2-98.4) pre and post embalming respectively. Pre and post embalming PPV was 89.3% (95.0% CI:71.8-97.7) and 83.3% (95.0% CI:65.3-94.4) respectively. The AUC pre-and post embalming was 94.9% (95% CI: 89.6 - 100) and 93.9% (95% CI, 88.5 - 99.4) respectively. Conclusions: The study showed a relatively high performance sensitivity and specificity of OraQuick® HIV-1/2 test among decedents, similar to those observed among living subjects. OraQuick® HIV-1/2 presents a convenient and less invasive screening test for surveillance of HIV among decedents within a mortuary setting.